TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3816096

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 30970442

Group type: EXPERIMENTAL
Intervention: PPI plus alginate (combination)
Number of subjects: 0

Group type: COMPARATOR
Intervention: PPI only
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alginate only (reference group)
Number of subjects: 0
Study: 26909669

Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg daily
Number of subjects: 5429

Group type: EXPERIMENTAL
Intervention: Clopidogrel 150 mg daily
Number of subjects: 5429

Group type: COMPARATOR
Intervention: Smoking status
Number of subjects: 5429
Study: 26377199

Group type: EXPERIMENTAL
Intervention: IPT of malaria at 3-month intervals using sulfadoxine-pyrimethamine and amodiaquine (n=127)
Number of subjects: 629

Group type: EXPERIMENTAL
Intervention: Iron-fortified complementary food (CF-FeFum) with 2 mg iron as NaFeEDTA and 3.8 mg iron as ferrous fumarate 6 days per week (n=126)
Number of subjects: 629

Group type: EXPERIMENTAL
Intervention: Both CF-FeFum and IPT (n=124)
Number of subjects: 629

Group type: EXPERIMENTAL
Intervention: Consumption of porridge, an iron-fortified CF with the composition currently on the Ivorian market (CF-FePP) providing 2 mg iron as NaFeEDTA and 3.8 mg iron as ferric pyrophosphate 6 days per week (n=127)
Number of subjects: 629

Group type: COMPARATOR
Intervention: Normal diet and IPT-placebo (n=125)
Number of subjects: 629
Study: 24279701

Group type: EXPERIMENTAL
Intervention: Linezolid
Number of subjects: 1184

Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 1184

Group type: EXPERIMENTAL
Intervention: MRSA presence
Number of subjects: 1184
Study: 21410682

Group type: EXPERIMENTAL
Intervention: Histamine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 0
Study: 19660489

Group type: EXPERIMENTAL
Intervention: Oxycodone 5 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Oxycodone 10 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Oxycodone 20 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 16714498

Group type: EXPERIMENTAL
Intervention: Confidential registration in a screened area
Number of subjects: 302

Group type: COMPARATOR
Intervention: Control group (standard registration)
Number of subjects: 302
Study: 15365540

Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide aqueous (TAA‐AQ)
Number of subjects: 215

Group type: COMPARATOR
Intervention: Fluticasone propionate (FP)
Number of subjects: 215

Group type: COMPARATOR
Intervention: Mometasone furoate (MF)
Number of subjects: 215
Study: 11418354

Group type: EXPERIMENTAL
Intervention: Escalating interferon dose (6 MU alpha-2a thrice weekly for 3 months, then 3 MU thrice weekly for 3 months; escalated to 9 MU at 6 weeks if HCV RNA detectable at 4 weeks)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Standard treatment (6 MU alpha-2a thrice weekly for 3 months, then 3 MU thrice weekly for 3 months)
Number of subjects: 63
Study: 9545672

Group type: EXPERIMENTAL
Intervention: Cefozopran (CZOP) 10.0 mg/kg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Cefozopran (CZOP) 21.4 mg/kg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Cefozopran (CZOP) 40.0 mg/kg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Cefozopran (CZOP)
Number of subjects: 24
Study: 8393638

Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone dipropionate (BDP) 1 mg twice per day (n = 7)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (n = 8)
Number of subjects: 15
Study: 3540504

Group type: EXPERIMENTAL
Intervention: Clonidine (CLO) 0.36 mg daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propranolol (PRO) 160 mg daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ) 70 mg daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 27216984

Group type: EXPERIMENTAL
Intervention: Self-affirmation intervention
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Self-affirming implementation intention intervention
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: All conditions combined
Number of subjects: 65
Study: 26711179

Group type: EXPERIMENTAL
Intervention: High-dose ergocalciferol (vitamin D2)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158
Study: 24706268

Group type: EXPERIMENTAL
Intervention: Mannequin training and video feedback
Number of subjects: 36

Group type: COMPARATOR
Intervention: Mannequin training
Number of subjects: 36
Study: 21852389

Group type: EXPERIMENTAL
Intervention: Epley maneuver + 24 mg betahistine 2 times daily for 1 week
Number of subjects: 72

Group type: COMPARATOR
Intervention: Epley maneuver + placebo 2 times daily for 1 week
Number of subjects: 72

Group type: COMPARATOR
Intervention: Epley maneuver only
Number of subjects: 72
Study: 19592234

Group type: EXPERIMENTAL
Intervention: Surgical resection of liver metastases
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjuvant therapies
Number of subjects: 0
Study: 17598071

Group type: EXPERIMENTAL
Intervention: Topiramate (TPM)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Previous AEDs
Number of subjects: 47
Study: 15946283

Group type: EXPERIMENTAL
Intervention: Standard care plus plain ice
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Standard care plus flavoured ice
Number of subjects: 67

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 67
Study: 14551301

Group type: EXPERIMENTAL
Intervention: Intranodal (IN) administration of peptide-pulsed DC vaccines
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Intradermal (ID) administration of peptide-pulsed DC vaccines
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Intravenous (IV) administration of peptide-pulsed DC vaccines
Number of subjects: 27
Study: 10539100

Group type: EXPERIMENTAL
Intervention: First tube
Number of subjects: 95

Group type: COMPARATOR
Intervention: Second tube
Number of subjects: 95
Study: 8879440

Group type: EXPERIMENTAL
Intervention: Controlled diet (whole-food test diets)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Non-intervention control group
Number of subjects: 33
Study: 1813067

Group type: EXPERIMENTAL
Intervention: Cytosol protein content (4.15 mg/ml cut-off)
Number of subjects: 382

Group type: COMPARATOR
Intervention: Protein-poor group
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Protein-rich group
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Protein category
Number of subjects: 382
Study: 6337769

Group type: EXPERIMENTAL
Intervention: Triamterene (200 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Frusemide (80 mg daily) with indomethacin (150 mg daily)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Spironolactone (300 mg) with indomethacin (150 mg daily)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (100 mg) with indomethacin (150 mg daily)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Triamterene (200 mg) with indomethacin (150 mg daily)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Diflunisal (given to 12 subjects)
Number of subjects: 24
Study: 31943506

Group type: EXPERIMENTAL
Intervention: 3-month fluoropyrimidine-oxaliplatin adjuvant chemotherapy
Number of subjects: 474

Group type: COMPARATOR
Intervention: 6-month fluoropyrimidine-oxaliplatin adjuvant chemotherapy
Number of subjects: 474
Study: 31241539

Group type: EXPERIMENTAL
Intervention: DSAS insole with participant's own athletic footwear
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control condition (participant's own athletic footwear)
Number of subjects: 15
Study: 27054503

Group type: EXPERIMENTAL
Intervention: Internet-based instructor-led mindfulness intervention
Number of subjects: 118

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 118
Study: 26876083

Group type: EXPERIMENTAL
Intervention: TEG guided transfusion strategy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard management group
Number of subjects: 60
Study: 24617494

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 271

Group type: COMPARATOR
Intervention: Best Practice Care (BPC)
Number of subjects: 271
Study: 21982425

Group type: EXPERIMENTAL
Intervention: Bucindolol
Number of subjects: 2706

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2706
Study: 19148946

Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 8

Group type: COMPARATOR
Intervention: Cyclosporine (CsA)
Number of subjects: 8
Study: 17884363

Group type: EXPERIMENTAL
Intervention: Dobutamine-atropine stress echocardiography (DASE)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Electrocardiographic exercise testing (EET)
Number of subjects: 199
Study: 14720527

Group type: EXPERIMENTAL
Intervention: Admission troponin T (tnT) >/=0.1 microg/l (n=116)
Number of subjects: 516

Group type: EXPERIMENTAL
Intervention: ST-segment resolution <50% (n=301)
Number of subjects: 516

Group type: EXPERIMENTAL
Intervention: Combination of tnT elevation and no ST-segment resolution
Number of subjects: 516
Study: 12140636

Group type: EXPERIMENTAL
Intervention: 60‐min course with lecture, video, and individual proctoring
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (no specific intervention)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Suturing assist device
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Standard laparoscopic instruments
Number of subjects: 17
Study: 9709844

Group type: EXPERIMENTAL
Intervention: Postoperative talocalcaneal (TC) angle
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Functional Rating System (FRS) of Laaveg and Ponseti
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Talocalcaneal angle (AP), talonavicular angle (AP and lateral), calcaneometatarsal V angle
Number of subjects: 62
Study: 8295050

Group type: EXPERIMENTAL
Intervention: Morphine (MS)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 68
Study: 2732524

Group type: EXPERIMENTAL
Intervention: Phenol neurolytic block
Number of subjects: 28

Group type: COMPARATOR
Intervention: Cryogenic block
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 28
Study: 31220200

Group type: EXPERIMENTAL
Intervention: In-person 60-min incontinence self-management workshop
Number of subjects: 909

Group type: COMPARATOR
Intervention: Control healthy ageing workshop
Number of subjects: 909
Study: 28216660

Group type: EXPERIMENTAL
Intervention: FCR (Fludarabine, Cyclophosphamide, Rituximab)
Number of subjects: 215

Group type: COMPARATOR
Intervention: FCM-R (Fludarabine, Cyclophosphamide, Mitoxantrone, Rituximab)
Number of subjects: 215
Study: 26033641

Group type: EXPERIMENTAL
Intervention: Losmapimod 15 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Losmapimod 7.5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Losmapimod 2.5 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Losmapimod 7.5 mg and 15 mg
Number of subjects: 0
Study: 23218449

Group type: EXPERIMENTAL
Intervention: Computerized asthma detection system
Number of subjects: 704

Group type: COMPARATOR
Intervention: Standard processes for control patients
Number of subjects: 704
Study: 21792695

Group type: EXPERIMENTAL
Intervention: Absolute survival framing format
Number of subjects: 2552

Group type: EXPERIMENTAL
Intervention: Absolute mortality framing format
Number of subjects: 2552

Group type: EXPERIMENTAL
Intervention: Relative mortality reduction framing format
Number of subjects: 2552

Group type: EXPERIMENTAL
Intervention: Fully informed condition
Number of subjects: 2552

Group type: COMPARATOR
Intervention: Comparison to fully informed condition
Number of subjects: 2552
Study: 18987880

Group type: EXPERIMENTAL
Intervention: Direct experience condition (participants saw simple events directly perceived)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Indirectly conveyed information conditions (information about the object, kind of event, or both were verbally conveyed)
Number of subjects: 0
Study: 16079172

Group type: EXPERIMENTAL
Intervention: Combination therapy (etanercept 25 mg twice weekly + methotrexate up to 20 mg weekly)
Number of subjects: 682

Group type: COMPARATOR
Intervention: Methotrexate (MTX) up to 20 mg weekly
Number of subjects: 682

Group type: COMPARATOR
Intervention: Etanercept (25 mg twice weekly)
Number of subjects: 682

Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 682

Group type: EXPERIMENTAL
Intervention: Combination therapy and etanercept
Number of subjects: 682
Study: 12545341

Group type: EXPERIMENTAL
Intervention: basiliximab 1 x 40-mg group
Number of subjects: 202

Group type: COMPARATOR
Intervention: basiliximab 2 x 20-mg group
Number of subjects: 202
Study: 10924561

Group type: EXPERIMENTAL
Intervention: Group A (180 mL of iopromide containing 370 mg of iodine per milliliter)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Group B (180 mL of iopromide containing 300 mg of iodine per milliliter)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Group A
Number of subjects: 102
Study: 8831332

Group type: EXPERIMENTAL
Intervention: Clonidine (2 micrograms/kg bolus followed by infusion at 2 micrograms.kg-1.h-1)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Clonidine (4 micrograms/kg bolus followed by infusion at 4 micrograms.kg-1.h-1)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 6
Study: 1486258

Group type: EXPERIMENTAL
Intervention: carteolol 2%
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: carteolol 2% suspended with liposomes (FAT-MLVs)
Number of subjects: 50
Study: 3973383

Group type: EXPERIMENTAL
Intervention: 6 micrograms HA of trivalent surface-antigen influenza virus vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3678549

Group type: EXPERIMENTAL
Intervention: Tenoxicam (oral and intradermal administration)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tenoxicam, piroxicam, and benoxaprofen (10-40 micrograms/ml) in vitro
Number of subjects: 0
Study: 29220876

Group type: EXPERIMENTAL
Intervention: New HFC (FIBRYGA, Octapharma AG)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control (Haemocomplettan® P/RiaSTAP™, CSL Behring GmbH)
Number of subjects: 22
Study: 28700496

Group type: EXPERIMENTAL
Intervention: Subliminal priming‐plus‐subliminal reward stimuli (experimental)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Subliminal priming‐plus‐supraliminal reward stimuli (control)
Number of subjects: 50
Study: 25813447

Group type: EXPERIMENTAL
Intervention: Pazopanib (800 mg once daily) for 8 to 16 weeks
Number of subjects: 25
Study: 23649780

Group type: EXPERIMENTAL
Intervention: Weight Bearing (WB) protocol
Number of subjects: 38

Group type: COMPARATOR
Intervention: Non-Weight Bearing (NWB) protocol
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Affected legs (both groups)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Shock absorption (both groups)
Number of subjects: 38
Study: 20233522

Group type: EXPERIMENTAL
Intervention: C-length guided method
Number of subjects: 637

Group type: COMPARATOR
Intervention: 15-cm guided method
Number of subjects: 637
Study: 18185107

Group type: EXPERIMENTAL
Intervention: cTBS (continuous Theta Burst Stimulation)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 0
Study: 16756783

Group type: EXPERIMENTAL
Intervention: Behavior therapy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Routine clinical care
Number of subjects: 100
Study: 14761115

Group type: EXPERIMENTAL
Intervention: GCF IFN-gamma levels at progressing sites
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Clinical measurements (gingival index, plaque index, bleeding on probing, probing depth, attachment loss)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Progression of periodontitis
Number of subjects: 33
Study: 11025394

Group type: EXPERIMENTAL
Intervention: Phyto Hypophyson L
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study: 8979740

Group type: EXPERIMENTAL
Intervention: Amiodarone therapy
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control (no amiodarone therapy)
Number of subjects: 200
Study: 1632533

Group type: EXPERIMENTAL
Intervention: Ketorolac (30 mg IV)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Morphine (5 mg IV)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Ketorolac (10 mg)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 6152615

Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Common emulsion antacid
Number of subjects: 0
Study: 30794574

Group type: EXPERIMENTAL
Intervention: Increased font size
Number of subjects: 6255

Group type: EXPERIMENTAL
Intervention: Describing indications for use on the label
Number of subjects: 6255

Group type: EXPERIMENTAL
Intervention: Describing contraindications on the label
Number of subjects: 6255

Group type: EXPERIMENTAL
Intervention: Highlighting the expiration date on the label
Number of subjects: 6255

Group type: EXPERIMENTAL
Intervention: New simulated package design with increased font size, color to highlight concentration, and contrast between font color and background
Number of subjects: 6255

Group type: COMPARATOR
Intervention: Standard design
Number of subjects: 6255

Group type: EXPERIMENTAL
Intervention: Overall readability and comprehensibility of medication labels
Number of subjects: 6255
Study: 30080980

Group type: EXPERIMENTAL
Intervention: Special diets
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control period
Number of subjects: 32
Study: 27106162

Group type: EXPERIMENTAL
Intervention: LMA Supreme
Number of subjects: 84

Group type: COMPARATOR
Intervention: LMA ProSeal
Number of subjects: 84
Study: 25171074

Group type: EXPERIMENTAL
Intervention: Lidocaine gel 2%
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Lidocaine gel 3.5%
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Lidocaine gel 5%
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Lidocaine gel 8%
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Lidocaine gel 12%
Number of subjects: 260

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 260
Study: 22323482

Group type: COMPARATOR
Intervention: Myeloablative conditioning
Number of subjects: 832

Group type: EXPERIMENTAL
Intervention: Reduced‐intensity conditioning (RIC)
Number of subjects: 832
Study: 20616293

Group type: EXPERIMENTAL
Intervention: Family medicine setting (n = 116)
Number of subjects: 847

Group type: COMPARATOR
Intervention: Specialized reproductive health clinics (n = 731)
Number of subjects: 847
Study: 17765245

Group type: EXPERIMENTAL
Intervention: Rosiglitazone 4 mg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Gliclazide 80 mg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Gliclazone 80 mg
Number of subjects: 50
Study: 15661116

Group type: EXPERIMENTAL
Intervention: ECT + active rTMS
Number of subjects: 22

Group type: COMPARATOR
Intervention: ECT + sham rTMS
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: ECT (both groups)
Number of subjects: 22
Study: 12492181

Group type: EXPERIMENTAL
Intervention: H. pylori eradication (cure)
Number of subjects: 1165

Group type: COMPARATOR
Intervention: Persistent H. pylori infection (control)
Number of subjects: 1165
Study: 9665113

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (200,000 IU for children > 1 year; 100,000 IU for infants)
Number of subjects: 687

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 687

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 687
Study: 19496272

Group type: EXPERIMENTAL
Intervention: Fluvastatin 40 mg twice daily, commencing at least 2 weeks before planned PICA
Number of subjects: 730
Study: 2668397

Group type: EXPERIMENTAL
Intervention: Thymomodulin (120 mg/day)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 326332

Group type: EXPERIMENTAL
Intervention: Retrobulbar injection of triamcinolone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 30001171

Group type: EXPERIMENTAL
Intervention: Sodium selenite (SEL+)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normal saline (SEL-)
Number of subjects: 40
Study: 30360536

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 436

Group type: EXPERIMENTAL
Intervention: Healthy Eating (HE)
Number of subjects: 436

Group type: EXPERIMENTAL
Intervention: Physical Activity (PA)
Number of subjects: 436

Group type: EXPERIMENTAL
Intervention: Healthy Eating (HE) and Physical Activity (PA)
Number of subjects: 436

Group type: EXPERIMENTAL
Intervention: GWG over the median at 35⁻37 weeks
Number of subjects: 436
Study: 26519191

Group type: EXPERIMENTAL
Intervention: Velpatasvir (VEL; GS‐5816)
Number of subjects: 0
Study: 24790703

Group type: EXPERIMENTAL
Intervention: Tai Chi exercise 5 days a week for 6 months
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control group (no Tai Chi)
Number of subjects: 71
Study: 22142020

Group type: EXPERIMENTAL
Intervention: Caffeine 3 mg x kg(‐1) body mass
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Caffeine 6 mg x kg(‐1) body mass
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 20112481

Group type: EXPERIMENTAL
Intervention: Abdominal acupuncture
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Conventional acupuncture
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Combined group (abdominal acupuncture plus conventional acupuncture)
Number of subjects: 105
Study: 17451415

Group type: EXPERIMENTAL
Intervention: Enamel matrix protein derivative (EMD) + bioactive glass (BG)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Enamel matrix protein derivative (EMD) alone
Number of subjects: 25
Study: 15237003

Group type: EXPERIMENTAL
Intervention: Soy phytoestrogens (150 mg of isoflavones per day) for 5 years
Number of subjects: 376

Group type: COMPARATOR
Intervention: Placebo tablets for 5 years
Number of subjects: 376
Study: 12564661

Group type: EXPERIMENTAL
Intervention: Structured care with atorvastatin 10-80 mg
Number of subjects: 1600

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1600

Group type: EXPERIMENTAL
Intervention: Structured care with atorvastatin 10-20 mg
Number of subjects: 1600